Physician profile
Michael D Williams
NPI 1336527746
$1,916.11
in general payments reported to CMS, 2019-2025
26 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2022: $218 · 2023: $306 · 2024: $301 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Goode Surgical INC | $604.00 | 2019 | |
| Abbvie INC. | $303.53 | 2022-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $130.73 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $90.93 | 2023-2024 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $89.36 | 2022-2024 | |
| Glaxosmithkline, LLC. | $86.13 | 2023-2025 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $79.55 | 2022-2025 | |
| Abbott Laboratories | $74.73 | 2023-2025 | Freestyle Libre 3, Eterna |
| Astrazeneca Pharmaceuticals LP | $58.94 | 2022-2024 | Farxiga, Airsupra |
| Amgen INC. | $50.63 | 2022-2025 | Otezla, Repatha, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.80 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $33.91 | 2022-2024 | Vaxneuvance, Proquad, Gardasil 9 |
| Pfizer INC. | $33.37 | 2023-2024 | |
| Axsome Therapeutics, INC. | $25.97 | 2024 | Auvelity |
| Astellas Pharma US INC | $24.08 | 2025 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $23.88 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.27 | 2022 | |
| Becton, Dickinson and Company | $19.22 | 2024 | Bd Onclarity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.90 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $17.70 | 2023 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $16.77 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.76 | 2022 | |
| Dynavax Technologies Corporation | $16.53 | 2022 | |
| Verona Pharma, INC. | $14.37 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $13.20 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.